National Cancer Institute (nci)

This study tests a vaccine called SurVaxM in 80 current or former smokers at high risk for lung cancer. The vaccine trains the immune system to attack cells that make a protein called survivin, which is common in cancer cells. The goal is to see if the vaccine can trigger a stron…

This phase II trial is testing whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for people with high-risk clear cell kidney cancer that hasn't spread. The 16 participants will receive the drugs before their kidney removal s…

This study tests whether adjusting chemotherapy and supportive care doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by RUNX1 gene mutations. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-mat…

This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …

This phase II trial tests whether adding the drug venetoclax to standard chemotherapy and a stem cell transplant helps adults with acute myeloid leukemia (AML) stay in remission. About 244 participants will receive either venetoclax or a placebo before and after their transplant.…

This phase 2 trial tests a new vaccine (TriAdeno) plus an immune-boosting drug (N-803) in 52 men with early-stage prostate cancer who are currently on active surveillance. The goal is to see if the combination can increase immune cell activity inside the tumor and possibly slow o…

This phase 2 trial tests whether combining two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of patients with stage II or III colorectal cancer after standard treatment. The study enrolls 20 adults whose blood tests still s…

This study tests whether the immunotherapy drug atezolizumab can prevent stage I non-small cell lung cancer from returning after surgery. About 336 people who have had their tumor completely removed will either receive the drug or be watched closely. The goal is to see if the tre…

This early-phase trial tests a new two-drug combination for people whose glioblastoma (a severe brain cancer) has returned after initial treatment. The first drug, Actimab-A, is a radioactive antibody designed to seek out and destroy cancer cells. The second, cemiplimab, helps th…

This study tests whether a new two-drug combination (daratumumab and teclistamab) works better than standard three-drug combos for people with high-risk multiple myeloma that has returned or not responded to one prior treatment. About 80 adults will be randomly assigned to receiv…

This phase II trial tests whether a combination of two drugs—sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) and bevacizumab (which cuts off tumor blood supply)—works better than standard chemotherapy for women with platinum-sensitiv…

This early-phase trial tests a new radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researcher…

This clinical trial is for people whose Hodgkin lymphoma has returned or not responded to first treatment. It has two parts: one for standard-risk patients testing a combination of targeted drugs (brentuximab vedotin and nivolumab) plus radiation, and another for high-risk patien…

This study compares a new combination of teclistamab and pomalidomide against the standard three-drug regimen (carfilzomib, pomalidomide, dexamethasone) for multiple myeloma that has come back after initial treatment. About 162 participants will receive either the new or standard…

This study tests whether adding epoetin alfa or emavusertib to luspatercept helps people with low-risk myelodysplastic syndrome (MDS) and anemia. MDS is a bone marrow disorder that leads to low blood counts. The goal is to see if these combinations improve red blood cell producti…

This study tests if combining different chemotherapy drugs can better eliminate leftover leukemia cells in adults aged 18-59 before they receive a stem cell transplant. Participants will receive one of four treatment plans, including standard care or newer combinations. The goal …

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This early-stage trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has come back or not improved after prior therapy. The drug works by attaching to both cancer cells and immune cells, helping the immune system attack the lymphoma. The study aims…

This study tests adding a new drug, iberdomide, to standard chemoimmunotherapy for children and young adults (ages 1-30) whose neuroblastoma has returned, not responded, or worsened after prior treatment. The goal is to see if the combination is safe and works better at controlli…

This early-phase study tests a personalized cell therapy for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that came back after standard treatment. Researchers take a patient's own immune cells, modify them to recognize a protein called B7-H…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests the safety and best dose of glofitamab when given with standard chemotherapy (R-CHOP/R-DHAP) for people with untreated mantle cell lymphoma. About 16 adults aged 18 to 75 with stage II bulky, III, or IV disease will take part. The goal is to see if ad…

This study tests whether adding the drug olutasidenib to standard treatments helps people with certain types of blood cancer (MDS or AML) that have an IDH1 gene mutation. About 132 adults will take part. The goal is to see if the new combination leads to higher remission rates an…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer ce…

This phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…

This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation.…

This study screens up to 1,000 people with personal or family histories of certain cancers or genetic syndromes to see if they qualify for one of six ongoing NCI genetics research studies. Participants fill out a 15-20 minute online questionnaire about their health, family histor…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…